SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors digest news of its high-volume production of HBM4 memory for Nvidia's new Vera Rubin AI platform, significantly boosting sentiment ahead of its upcoming earnings report. The community is heavily focused on the stock's massive year-to-date rally and the potential for a sustained memory 'supercycle,' with fierce debate between bulls expecting further breakout growth and bears warning of an overheated, overvalued valuation.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is trending following a volatile IPO debut, with traders actively debating its potential as a drone autonomy software play in the defense sector. The community is focused on its combat-tested technology used in Ukraine and discussing the risks versus rewards of chasing the stock's significant intraday price swings.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending after a short seller report from Muddy Waters triggered sharp intraday volatility, prompting CEO Anthony Noto to publicly defend the company and aggressively buy additional shares in a show of confidence. Investors are actively debating the report's allegations while many view the swift price recovery as a sign that the short-lived dip served primarily as a liquidity exit for the short sellers.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon shares are facing downward pressure as investors weigh disappointing revenue and earnings guidance against ongoing leadership instability and a high-profile board proxy contest. While the stock continues to see high trading volume from market participants monitoring potential activist interventions and a long-awaited CEO transition, sentiment remains polarized between those anticipating a recovery and those concerned about brand saturation and increased competition.

General Mills, Inc. engages in the manufacture and marketing of branded consumer foods sold through retail stores. Its product categories include snacks, ready-to-eat cereal, convenient meals, pet food, refrigerated and frozen dough, baking mixes and ingredients, yogurt, and ice cream. It operates through the following segments: North America Retail, International, North America Pet, and North America Foodservice. The North America Retail segment includes grocery stores, mass merchandisers, membership stores, natural food chains, drug, dollar and discount chains, convenience stores, and e-commerce grocery providers. The International segment refers to the retail and foodservice businesses outside of the US and Canada. The North America Pet segment includes pet food products sold in national pet superstore chains, e-commerce retailers, grocery stores, regional pet store chains, mass merchandisers, and veterinary clinics and hospitals. The North America Foodservice segment offers ready-to-eat cereals, snacks, refrigerated yogurt, frozen meals, unbaked and fully baked frozen dough products, baking mixes, and bakery flour. The company was founded by Cadwallader C. Washburn on June 20, 1928 and is headquartered in Minneapolis, MN.

General Mills, Inc.

General Mills is seeing heightened trading interest and community debate ahead of its upcoming earnings report, with investors focused on how the company manages margin pressure and shifting consumer demand. While some traders are bottom-fishing on the stock's recent price weakness and its defensive dividend profile, others remain cautious about the long-term impact of evolving dietary trends and the competitive landscape for packaged food brands.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI Corp. is surging as investors react to a significant new defense contract for missile propulsion subsystems, fueling bullish sentiment despite heavy short interest. The community is actively debating the company's potential as a defense industry "prime" player while monitoring technical breakouts and high institutional trading volume.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is currently facing intense selling pressure and negative sentiment driven by a highly publicized audit report from a third-party consultant that suggests potential service agreement violations, which the company has officially refuted. Investors are actively debating the legitimacy of these claims and the CEO's recent significant personal share purchases, with many expressing deep frustration over the stock's persistent volatility and perceived lack of institutional support.

Macy's, Inc. engages in the retail of apparel, accessories, cosmetics, home furnishings, and other consumer goods. The firm's brands include Macy's, Bloomingdale's, and Bluemercury. It offers men's, women's, and children's apparel, women's accessories, intimate apparel, shoes, cosmetics, fragrances, as well as home and miscellaneous products. The company was founded by Rowland H. Macy in 1858 and is headquartered in New York, NY.

Macy`s Inc

Macy's Inc

Macy's is trending as investors digest a mixed but resilient quarterly report, with the company beating earnings expectations while issuing a cautious outlook on holiday spending due to macroeconomic headwinds. The conversation among market participants is heavily focused on the viability of the company's 'Bold New Chapter' turnaround strategy and ongoing speculation regarding potential buyout interest in its vast real estate holdings.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is experiencing extreme volatility and intense community speculation driven by a combination of a structural memory chip shortage, speculative trading activity, and anticipation surrounding upcoming earnings and industry events. While some traders are aggressively riding the momentum, others are debating whether the current price levels reflect a durable super-cycle or a speculative bubble prone to a sharp reversal.

SailPoint, Inc. engages in the provision of a comprehensive identity security platform for the enterprise. Its solutions enable organizations to establish, control, and automate policies that help them define and maintain a robust security posture and achieve regulatory compliance. The company was founded by Mark David McClain in 2005 and is headquartered in Austin, TX.

Sailpoint Inc.

SailPoint Technologies Holdings Inc

SailPoint Technologies is drawing investor scrutiny as some market participants weigh the potential displacement of its identity governance platform by AI agents that can automate permissions within cloud environments. While the company positions its identity control plane as an essential security backbone for the AI-powered enterprise, investors remain divided on whether this legacy-style architecture can maintain its moat against more agile, AI-native competitors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

- Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales -- Rasayana to assume all responsibility and costs for SYN-020 development and commercialization -ROCKVILLE, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported the out-licensing of SYN-020, to Rasayana Therapeutics, Inc., a privately-held company targeting the Gut-Organ axis biology to discover and deliver transformative gut-targeted medicines for patients with chronic inflammatory diseases.&nbsp;SYN-020 is a recombinant bovine intestinal alkaline phosphatase (IAP) produced under cGMP conditions and formulated for oral delivery to the small intestine. It is designed to reduce fat absorption and intestinal inflammation; tighten the gut barrier to mitigate leaky gut; and promote a healthy microbiome. These modes-of-action mean SYN-020 has the potential to address multiple metabolic and inflammatory disorders and diseases associated with aging. SYN-020 was well tolerated in Phase 1 clinical studies and is now poised to enter Phase 2 clinical testing with Rasayana.“We are extremely pleased to complete the license of SYN-020 to Rasayana, which will enable the advancement of this important GI asset from our portfolio while we focus on our lead pancreatic cancer program, VCN-01,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We believe SYN-020 is a highly versatile asset with therapeutic opportunities in multiple high-value indications arising from GI dysfunction. The Rasayana team and advisors are world leaders in IAP and its clinical applications, and they are well positioned to advance SYN-020 development, ideally delivering benefits for patients and value for Theriva shareholders.”&nbsp;“We are thrilled to partner with Theriva Biologics on the development of SYN-020,” said Vidisha Mohad, Founder and CEO of Rasayana Therapeutics. “SYN-020 offers a fundamentally innovative approach to addressing gastrointestinal dysfunction and its systemic health implications. Having worked on SYN-020 research during my postdoctoral training at Harvard, I have deep conviction in its underlying biology, scientific rigor, and therapeutic potential. Importantly, its cost-effective profile reflects our shared commitment to making transformative treatments accessible to patients who need them most. At Rasayana, we are focused on advancing therapies that target the Gut-Organ Axis to extend healthspan. SYN-020’s novel biology, strong safety profile, and compelling clinical data make it an ideal fit for our pipeline. We look forward to building on Theriva’s foundational work and accelerating this program to deliver meaningful outcomes for patients worldwide”.Under the terms of the agreement, Rasayana is granted an exclusive, worldwide license, with the right to sublicense, to develop and commercialize SYN-020 for therapeutic and diagnostic use. Theriva received a $300,000 up-front payment at signing and is eligible for up to $16M in development and regulatory milestones, tiered single digit royalties on net product sales, and up to $22M in milestones payable upon achievement of certain annual aggregate net sales. Rasayana will assume all responsibility and costs for SYN-020 development and commercialization.&nbsp;About Theriva™ Biologics,&nbsp;Inc.Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; and (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. For more information, please visit Theriva Biologics’ website at&nbsp;www.therivabio.com.&nbsp;About Rasayana Therapeutics, Inc.Rasayana Therapeutics, Inc. is a biotechnology company targeting the Gut-Organ axis biology to address chronic inflammatory diseases. The company is pioneering a new class of gut-inflammation targeting therapies for gastrointestinal, cardiometabolic, and neurodegenerative diseases. Rasayana’s mission is to develop novel, cost-effective medicines that extend healthspan and improve quality of life for patients globally. For more information, visit Rasayana Therapeutics website at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=hLZTfPu2_0SymExk02qvUbsHQ8p-vzyMwruJmpooYqOW89Jp-kMpNRBCkyuLct-aQ1rNR0NhLwOo3WO03RLPjHGEKhHV6et5B6zWcDjISACDR3DgYde0lTEIZ5vW-puz">www.rasayanatherapeutics.com</a>Forward-Looking StatementThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding SYN-020 having the potential to address multiple metabolic and inflammatory disorders and diseases associated with aging; SYN-020 being poised to enter into Phase 2 clinical testing with Rasayana; enabling the advancement of this important GI asset; SYN-020 being a highly versatile asset with therapeutic opportunities in multiple high-value indications arising from GI dysfunction; and Rasayana being well positioned to advance SYN-020 development and deliver benefits for patients and value for Theriva shareholders; and SYN-020’s therapeutic potential accelerating the SYN-020 program to deliver meaningful outcomes for patients worldwide; and Theriva receiving up to $16M in development and regulatory milestones, tiered single digit royalties on net product sales, and up to $22M in milestones payable upon achievement of certain annual aggregate net sales . Important factors that could cause actual results to differ materially from current expectations include, among others, Rasayana’s ability to reach clinical milestones when anticipated including entering into Phase 2 clinical testing of SYN-020 , the ability generate clinical data that establishes SYN-020 may deliver benefits for patients and have therapeutic potential; Rasayana’s ability to achieve development and commercialization milestones as well as sales that result in payments to Theriva; SYN-020 and the Company’s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results; the ability to complete clinical trials on time and achieve the desired results and benefits; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s and Rasyana’s ability to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of the Company’s and Rasayana’s products, developments by competitors that render such products obsolete or non-competitive, the ability to maintain license agreements, the continued maintenance and growth of the Company’s patent estate, the ability to continue to remain well financed and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.For further information, please contact:Investor Relations: Kevin Gardner LifeSci Advisors, LLC kgardner@lifesciadvisors.comSource: Theriva Biologics, Inc.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications

Theriva Biologics licenses SYN-020 to Rasayana for $300k upfront and up to $38M in future milestones.

Others

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong on Saturday, 07 February 2026 –- Preclinical data will highlight synergistic antitumor activity for the combination of topotecan and VCN-01 that may improve outcomes in refractory retinoblastoma patients with difficult-to-treat vitreous seeds -&nbsp;ROCKVILLE, Md. and BARCELONA, Spain, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced an invited presentation of clinical outcomes and safety data from the investigator sponsored Phase 1 clinical study (NCT03284268) evaluating the safety and tolerability of two intravitreal injections of VCN-01 (zabilugene almadenorepvec) in pediatric patients with intraocular retinoblastoma that was refractory to systemic, intra-arterial, or intravitreal chemotherapy, and for whom enucleation was the only recommended treatment. Preclinical data describing the synergistic antitumor effects observed when topotecan (a standard of care chemotherapy for retinoblastoma) is coadministered with VCN-01 will also be presented. These data will be presented during a retinoblastoma focused session at the upcoming Asia-Pacific Academy of Ophthalmology (APAO) Congress (held in conjunction with the 37thAnnual Scientific Meeting Hong Kong Ophthalmological Symposium) taking place in Hong Kong, China, 5-8 February 2026.&nbsp;Details of the presentation can be found <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=tNHDcbYkw6QgsozmQVCV8LQ4aTYsU_XNvjMA_g5TstEs-pckD_WX3j9BnnaHV3_z_8or3c9jjqdEB_nzrNUBX_jnp8z0HlzdOtuLudXTyKWHRFH-9eJtNAXRMj_D30Uj">online</a> and below.<ul><li>Presenting Author: Dr. Jaume Català-Mora, Pediatric Ophthalmologist, Sant Joan de Déu-Barcelona Children’s Hospital</li><li>Title: Update on Oncolytic Adenovirus VCN-01 Trial in Retinoblastoma</li><li>Session: 0211 Retinoblastoma in Association With Asian Retinoblastoma Group</li><li>Date &amp; Time: Saturday 07 February, 2026, at 4:46 PM HKT (3:46 AM US EDT)</li><li>Location: Rooms S224-225, Level 2, Hong Kong Convention and Exhibition Centre (HKCEC) &nbsp;</li></ul>“We are very pleased with the on-going international interest in the novel clinical and preclinical findings by our collaborators treating retinoblastoma patients at Sant Joan de Déu-Barcelona Children’s Hospital,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “Effective treatment of refractory retinoblastoma with vitreous seeds remains a significant unmet medical need for pediatric patients with this condition worldwide. Based on our previously reported Phase 1 clinical <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=ndEUifZXBX0beJKpblsn4l3WNy9v6SPzYN6472Z3tMuJHqxLesgsKvlFh8uhvvcve7VvQloR2cb6CQLkjepQg6nwP98Ywnl5KBtO-ct4zKeDD8Jz0o3wHfOvKHaNIGeu">data</a>, and the emerging preclinical findings, we believe that the intravitreal combination of VCN-01 and topotecan provides an exciting new opportunity to address this challenge and help preserve the eyes and quality-of-life of children with this rare but devastating cancer. VCN-01 has Orphan Drug and Rare Pediatric Disease designations for the treatment of retinoblastoma, and we are currently refining a potential pivotal clinical trial design in this indication for discussion with regulatory agencies.”About VCN-01VCN-01 (zabilugene almadenorepvec) is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive barrier to cancer treatment. This unique mode-of-action enables VCN-01 to exert multiple antitumor effects by (i) selectively infecting and lysing tumor cells; (ii) enhancing the access and perfusion of co-administered chemotherapy products; and (iii) increasing tumor immunogenicity and exposing the tumor to the patient’s immune system and co-administered immunotherapy products. Systemic administration enables VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered to over 140 patients to date in clinical trials of different cancers, including PDAC (in combination with chemotherapy), head and neck squamous cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma (by intravitreal injection). More information on these clinical trials is available at Clinicaltrials.gov. VCN-01 has Orphan Drug designation from the EMA and both Orphan Drug designation and Fast Track designation from the FDA for the treatment of pancreatic cancer. VCN-01 also has Orphan Drug designation and Rare Pediatric Diseases designation from the FDA for the treatment of retinoblastoma.&nbsp;About RetinoblastomaRetinoblastoma is a tumor that originates in the retina and is the most common type of eye cancer in children. It occurs in approximately 1/14,000 - 1/18,000 live newborns and accounts for 15% of the tumors in the pediatric population &lt; 1 year old. The average age of pediatric patients at diagnosis is 2, and it rarely occurs in children older than 6. In Europe, retinoblastoma has an estimated incidence rate of 1 per 13,844 live births (14.1 per million children under the age of 5) with approximately 300 children diagnosed per year (<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=bdwE4r7sy1MWwrIxf22JOGA7c7zt9J7zsbC2MgiwMD8ROr7SJbrucThnwSGxmDz3MR6uvdjupNm4w-W6JM2T5_ku9I7MZPAeSsHo5R3xqvYwAeWlPPIsoPoud3fUA4hI7f9FTUupCfakveniiQ3-dA==">Stacey et al. 2021</a>). Preserving life and preventing the loss of an eye, blindness, and other serious effects of treatment that reduce the patient’s life span or the quality of life remains a challenge. In addition, children with retinoblastoma have been more likely to lose their eye and die of metastatic disease in low-resource countries.&nbsp;About Theriva™ Biologics, Inc.Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L. , has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidates are: (1) VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients); and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=dhFmQsJ81g_9OUj8i5TBL_CFPWIb7PtqMyHERYhfHsp6p66lc6VlPfbfa-7P-87mJe7mfoiWVuHGo4O2RW3qYaNVBN7de2bMxaS2kOzZKz0=">www.therivabio.com</a>.&nbsp;Forward-Looking StatementThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding preclinical data highlighting synergistic antitumor activity for the combination of topotecan and VCN-01 that may improve outcomes in refractory retinoblastoma patients with difficult-to-treat vitreous seeds; the intravitreal combination of VCN-01 and topotecan providing an exciting new opportunity to address the challenge of effective treatment of refractory retinoblastoma withvitreous seeds retinoblastoma and a potential pivotal clinical trial design in retinoblastoma These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to design a pivotal clinical trial in retinoblastoma for discussion with the FDA; VCN-01’s ability to have positive results in future trials for the treatment of retinoblastoma and other therapeutic benefits; the Company’s ability to reach clinical milestones when anticipated including enrolling the expected number of patients in each trial; the Company’s product candidates, including VCN-01, demonstrating safety and effectiveness, as well as results that are consistent with prior results; the ability to complete clinical trials on time and achieve the desired results and benefits, continuing clinical trial enrollment as expected; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of the Company’s products, developments by competitors that render such products obsolete or non-competitive, the Company’s ability to maintain license agreements, the continued maintenance and growth of the Company’s and VCN’s patent estate, the ability to continue to remain well financed, and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.For further information, please contact:Investor Relations: Kevin Gardner LifeSci Advisors, LLC kgardner@lifesciadvisors.comSource: Theriva Biologics, Inc.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026

Theriva Biologics to present VCN-01 Phase 1 and preclinical data for retinoblastoma at APAO 2026.

Shares of Theriva Biologics fell sharply after the company priced a public offering of up to 6.8 million shares of common stock and accompanying warrants at $1.10 per unit.&nbsp;The offering is expected to raise nearly $7.5 million in gross proceeds, before deducting placement agent fees and other offering expenses.&nbsp;The warrants will be exercisable immediately at the same price of $1.10 per share and will expire in five years.Theriva shares closed at $0.81, down 41% on Wednesday. After hours, shares dropped to $0.75, reflecting a further 7.4% decline.The offering follows the announcement of positive topline results from the Virage Phase 2b clinical trial, which evaluated VCN-01 in combination with standard chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (PDAC).&nbsp;The study, which included 96 newly diagnosed metastatic PDAC patients, showed that patients receiving VCN-01 plus chemotherapy had a median overall survival (OS) of 10.8 months, compared to 8.6 months in the control group receiving chemotherapy alone.&nbsp;Additionally, the VCN-01+chemotherapy arm showed a median duration of response (DoR) of 11.2 months, double that of the control arm’s 5.4 months.Theriva intends to use the proceeds primarily for working capital, general corporate purposes, and research and development.&nbsp;A portion of the funds may also be used for manufacturing scale-up or potential acquisitions, although no specific deals are currently in place.&nbsp;A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.On Stocktwits, sentiment was described as ‘extremely bullish’, with ‘high’ message volume fueling speculation about the company’s future.&nbsp;One user speculated that a buyout could still be in play, potentially happening before September 30. This user noted that while the offering would dilute the stock, buying at current levels could offer significant upside in the event of a buyout.<stembedurl>https://stocktwits.com/exwallstcfo/message/613861348</stembedurl>Another user drew comparisons between Theriva and Pasithea Therapeutics, suggesting that both companies had positive news followed by public offerings.&nbsp;The user speculated that the offering could have been strategically timed to benefit from a price pump.<stembedurl>https://stocktwits.com/Staceykyusa/message/613855430</stembedurl>Shares of Theriva have fallen nearly 51% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01.

Equity

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01, in combination with standard chemotherapy. 

Shares of <a href="https://stocktwits.com/symbol/TOVX">Theriva Biologics Inc</a>. (TOVX) surged over 30% on Friday, making it one of the top trending tickers on Stocktwits, coming on the heels of several key developments that have caught the attention of retail investors.The rally began on Thursday after Theriva Biologics announced it had received a notice of allowance for a U.S. patent application related to treating C. difficile and other antibiotic-induced gastrointestinal tract conditions.Additionally, Theriva recently secured Rare Pediatric Drug Designation (RPDD) from the U.S. FDA for VCN-01, its experimental treatment for retinoblastoma, the most common type of eye cancer in children. The condition affects 200 to 300 children annually in the U.S., mostly infants and young children, according to the American Cancer Society.“We continue to work closely with leading physicians and regulatory agencies to refine our clinical strategy for VCN-01 as an adjunct to chemotherapy in pediatric patients with advanced retinoblastoma,” Steven A. Shallcross, CEO of Theriva Biologics had said earlier.He added that the company also reported encouraging results from an investigator-sponsored Phase 1 trial evaluating VCN-01 in pediatric patients with refractory retinoblastoma.Beyond the scientific advancements, Theriva also executed a 1-for-25 reverse stock split, which began trading on a split-adjusted basis on August 26.Earlier this month, Theriva reported a Q2 loss of $0.43 per share, significantly narrower than the consensus estimate of a $0.70 loss. The company also said it was committed to expanding its portfolio of therapeutic combinations and reducing cash burn to extend its runway.<stembedurl>https://stocktwits.com/ANTHONYMOMO/message/584669011</stembedurl>These developments have sparked some retail interest, with TOVX’s follower count rising by 1.14% (suggest avoid saying considerable retail interest with 1.14% rise) in the past week, and message volume on Stocktwits jumping significantly.Despite being down nearly 50% year-to-date, the recent string of positive catalysts has sparked renewed optimism among investors about Theriva’s long-term prospects.Read Next: <a href="Lululemon Stock Rises After Mixed Q2 Report, But Retail Optimism Fades On Lowered Outlook">Lululemon Stock Rises After Mixed Q2 Report, But Retail Optimism Fades On Lowered Outlook</a>&nbsp;&nbsp; &nbsp;

TOVX Stock Jumps 30% As New Patent, FDA Designation Boost Investor Sentiment

Theriva recently secured Rare Pediatric Drug Designation (RPDD) from the U.S. FDA for VCN-01, its experimental treatment for retinoblastoma, the most common type of eye cancer in children.

What’s Getting Investors So Excited About TOVX Stock?

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.

TOVX
Theriva Biologics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest TOVX News

TOVXTheriva Biologics Inc